Cargando…

Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes

Mild traumatic brain injuries (mTBI) are common injuries across civilian and military populations. Although most individuals recover after mTBI, some individuals continue to show long-term symptoms as well as increased risk for neurodegenerative and neuropsychiatric disorders. Currently, diagnosing...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaughn, Melonie N., Winston, Charisse N., Levin, Natalie, Rissman, Robert A., Risbrough, Victoria B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866179/
https://www.ncbi.nlm.nih.gov/pubmed/35222223
http://dx.doi.org/10.3389/fneur.2021.698206
_version_ 1784655782010159104
author Vaughn, Melonie N.
Winston, Charisse N.
Levin, Natalie
Rissman, Robert A.
Risbrough, Victoria B.
author_facet Vaughn, Melonie N.
Winston, Charisse N.
Levin, Natalie
Rissman, Robert A.
Risbrough, Victoria B.
author_sort Vaughn, Melonie N.
collection PubMed
description Mild traumatic brain injuries (mTBI) are common injuries across civilian and military populations. Although most individuals recover after mTBI, some individuals continue to show long-term symptoms as well as increased risk for neurodegenerative and neuropsychiatric disorders. Currently, diagnosing TBI severity relies primarily on self-report and subjective symptoms, with limited tools for diagnosis or prognosis. Brain-derived exosomes, a form of extracellular vesicle, may offer a solution for interpreting injury states by aiding in diagnosis as well as outcome prediction with relatively low patient burden. Exosomes, which are released into circulation, contain both protein and RNA cargo that can be isolated and quantified, providing a molecular window into molecular status of the exosome source. Here we examined the current literature studying the utility of exosomes, in particular neuronal- and astrocyte-derived exosomes, to identify protein and miRNA biomarkers of injury severity, trajectory, and functional outcome. Current evidence supports the potential for these emerging new tools to capture an accessible molecular window into the brain as it responds to a traumatic injury, however a number of limitations must be addressed in future studies. Most current studies are relatively small and cross sectional; prospective, longitudinal studies across injury severity, and populations are needed to track exosome cargo changes after injury. Standardized exosome isolation as well as advancement in identifying/isolating exosomes from CNS-specific tissue sources will improve mechanistic understanding of cargo changes as well as reliability of findings. Exosomes are also just beginning to be used in model systems to understand functional effects of TBI-associated cargo such as toxicity. Finally linking exosome cargo changes to objective markers of neuronal pathology and cognitive changes will be critical in validating these tools to provide insights into injury and recovery states after TBI.
format Online
Article
Text
id pubmed-8866179
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88661792022-02-25 Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes Vaughn, Melonie N. Winston, Charisse N. Levin, Natalie Rissman, Robert A. Risbrough, Victoria B. Front Neurol Neurology Mild traumatic brain injuries (mTBI) are common injuries across civilian and military populations. Although most individuals recover after mTBI, some individuals continue to show long-term symptoms as well as increased risk for neurodegenerative and neuropsychiatric disorders. Currently, diagnosing TBI severity relies primarily on self-report and subjective symptoms, with limited tools for diagnosis or prognosis. Brain-derived exosomes, a form of extracellular vesicle, may offer a solution for interpreting injury states by aiding in diagnosis as well as outcome prediction with relatively low patient burden. Exosomes, which are released into circulation, contain both protein and RNA cargo that can be isolated and quantified, providing a molecular window into molecular status of the exosome source. Here we examined the current literature studying the utility of exosomes, in particular neuronal- and astrocyte-derived exosomes, to identify protein and miRNA biomarkers of injury severity, trajectory, and functional outcome. Current evidence supports the potential for these emerging new tools to capture an accessible molecular window into the brain as it responds to a traumatic injury, however a number of limitations must be addressed in future studies. Most current studies are relatively small and cross sectional; prospective, longitudinal studies across injury severity, and populations are needed to track exosome cargo changes after injury. Standardized exosome isolation as well as advancement in identifying/isolating exosomes from CNS-specific tissue sources will improve mechanistic understanding of cargo changes as well as reliability of findings. Exosomes are also just beginning to be used in model systems to understand functional effects of TBI-associated cargo such as toxicity. Finally linking exosome cargo changes to objective markers of neuronal pathology and cognitive changes will be critical in validating these tools to provide insights into injury and recovery states after TBI. Frontiers Media S.A. 2022-02-10 /pmc/articles/PMC8866179/ /pubmed/35222223 http://dx.doi.org/10.3389/fneur.2021.698206 Text en Copyright © 2022 Vaughn, Winston, Levin, Rissman and Risbrough. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Vaughn, Melonie N.
Winston, Charisse N.
Levin, Natalie
Rissman, Robert A.
Risbrough, Victoria B.
Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes
title Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes
title_full Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes
title_fullStr Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes
title_full_unstemmed Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes
title_short Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes
title_sort developing biomarkers of mild traumatic brain injury: promise and progress of cns-derived exosomes
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866179/
https://www.ncbi.nlm.nih.gov/pubmed/35222223
http://dx.doi.org/10.3389/fneur.2021.698206
work_keys_str_mv AT vaughnmelonien developingbiomarkersofmildtraumaticbraininjurypromiseandprogressofcnsderivedexosomes
AT winstoncharissen developingbiomarkersofmildtraumaticbraininjurypromiseandprogressofcnsderivedexosomes
AT levinnatalie developingbiomarkersofmildtraumaticbraininjurypromiseandprogressofcnsderivedexosomes
AT rissmanroberta developingbiomarkersofmildtraumaticbraininjurypromiseandprogressofcnsderivedexosomes
AT risbroughvictoriab developingbiomarkersofmildtraumaticbraininjurypromiseandprogressofcnsderivedexosomes